Cyberonics Seeks Suitor To Transform Into Premier Neuromodulation Firm
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics' aim to become the global neuromodulation leader following FDA approval of its VNS Therapy for treatment-resistant depression could depend on its attractiveness as an acquisition target